$PMHS
Polomar Health Services, Inc.

2023 Q3 Form 10-Q Financial Statement

#000166357723000441 Filed on August 23, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2023 Q1
Revenue $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $70.66K $90.96K $89.81K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $70.66K $90.96K $89.81K
YoY Change 291.58% 563.54%
Operating Profit -$70.66K -$90.96K -$89.81K
YoY Change 422.69% 563.54%
Interest Expense -$50.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$37.49K
YoY Change -48781.82%
Pretax Income -$108.1K -$90.96K -$89.81K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$108.1K -$90.96K -$89.81K
YoY Change 704.57% 563.54% 3891.38%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 108.6M shares 107.8M shares 108.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.08K $28.02K $198.3K
YoY Change
Cash & Equivalents $15.08K $28.02K $198.3K
Short-Term Investments
Other Short-Term Assets $0.00 $2.210K $4.060K
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00 $20.00K $20.00K
Other Receivables $113.9K $80.00K $0.00
Total Short-Term Assets $129.0K $130.2K $222.4K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $129.0K $130.2K $222.4K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $129.0K $130.2K $222.4K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.21K $7.670K $9.980K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $4.700K $6.360K $5.250K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.91K $14.03K $15.24K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $14.91K $14.03K $15.24K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $14.91K $14.03K $15.24K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$1.271M -$1.163M
YoY Change
Common Stock $109.1K $108.6K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $114.1K $116.2K $207.2K
YoY Change
Total Liabilities & Shareholders Equity $129.0K $130.2K $222.4K
YoY Change

Cashflow Statement

Concept 2023 Q3 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$108.1K -$90.96K -$89.81K
YoY Change 704.57% 563.54% 3891.38%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$117.3K -$171.4K $537.4K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 104.3K 1.110K -556.6K
YoY Change
NET CHANGE
Cash From Operating Activities -117.3K -171.4K 537.4K
Cash From Investing Activities
Cash From Financing Activities 104.3K 1.110K -556.6K
Net Change In Cash -12.93K -170.3K -19.21K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$117.3K -$171.4K $537.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Revenues
Revenues
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001265521
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q4 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
usd
CY2022Q2 TRFE Return And Cancellation Of Common Stock During Period
ReturnAndCancellationOfCommonStockDuringPeriod
usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
TRFE Return And Cancellation Of Common Stock
ReturnAndCancellationOfCommonStock
usd
CY2023Q2 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
usd
CY2022Q4 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56555
dei Entity Registrant Name
EntityRegistrantName
Trustfeed Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-1006313
dei Entity Address Address Line1
EntityAddressAddressLine1
140 Broadway
dei Entity Address Address Line2
EntityAddressAddressLine2
46th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10005
dei City Area Code
CityAreaCode
800-
dei Local Phone Number
LocalPhoneNumber
490-7454
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
108564879 shares
CY2023Q2 us-gaap Cash
Cash
28019 usd
CY2022Q4 us-gaap Cash
Cash
225619 usd
CY2023Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
20000 usd
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
30000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2205 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5865 usd
CY2023Q2 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
80000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
130224 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
261484 usd
CY2023Q2 us-gaap Assets
Assets
130224 usd
CY2022Q4 us-gaap Assets
Assets
261484 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7667 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5012 usd
CY2023Q2 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
6360 usd
CY2022Q4 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
69703 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
14027 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
74715 usd
CY2023Q2 us-gaap Liabilities
Liabilities
14027 usd
CY2022Q4 us-gaap Liabilities
Liabilities
74715 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
500000 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
500000 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
500 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
500 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
108564879 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
108564879 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
107582614 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107582614 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
108565 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
107582 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1169729 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1023476 usd
CY2022Q4 us-gaap Payable Common Stock Redeemed
PayableCommonStockRedeemed
37044 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1162597 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-981833 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
116197 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
186769 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
130224 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
261484 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
90958 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13708 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
180764 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15958 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
90958 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
13708 usd
us-gaap Operating Expenses
OperatingExpenses
180764 usd
us-gaap Operating Expenses
OperatingExpenses
15958 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-90958 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13708 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-180764 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-15958 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-90958 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-13708 usd
us-gaap Profit Loss
ProfitLoss
-180764 usd
us-gaap Profit Loss
ProfitLoss
-15958 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.04
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.05
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107807983 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
313577 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107793942 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
305784 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
186769 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
110192 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-89806 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
207155 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-90958 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
116197 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-35646 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2250 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-37896 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13708 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-51604 usd
us-gaap Net Income Loss
NetIncomeLoss
-180764 usd
us-gaap Net Income Loss
NetIncomeLoss
-15958 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3660 usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
80000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2655 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3709 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-244449 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12249 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
110192 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1657 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
12249 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
-65000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46849 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12249 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-197600 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
225619 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28019 usd
TRFE Return And Cancellation Of Common Stock
ReturnAndCancellationOfCommonStock
95000 usd
us-gaap Basis Of Accounting
BasisOfAccounting
<p id="xdx_842_eus-gaap--BasisOfAccounting_z1YDckms8rRc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt"><i><span style="text-decoration: underline">Basis of presentation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-align: justify">The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 13.95pt; text-align: justify">The financial statements have been prepared in accordance with accounting principles generally accepted in The United States of America and the rules and regulations of the OTC Markets alternative reporting standard for interim financial information. Accordingly, they do not include all the information necessary for a comprehensive presentation of financial position and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.95pt; text-align: justify">It is management's opinion, however, that all material adjustments (consisting of normal and recurring adjustments) have been made which are necessary for a fair financial statements presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year.</p> <p style="font: 8.5pt Times New Roman, Times, Serif; margin: 0.15pt 0 0; text-align: justify"> </p> <p style="font: 8.5pt Times New Roman, Times, Serif; margin: 0.15pt 0 0; text-align: justify"> </p> <p style="font: 8.5pt Times New Roman, Times, Serif; margin: 0.15pt 0 0; text-align: justify"></p>
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zPxymh4HAI9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt"><i><span style="text-decoration: underline">Use of estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14pt; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p>
CY2023Q2 us-gaap Cash
Cash
28019 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1162597 usd
us-gaap Net Income Loss
NetIncomeLoss
-180764 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-244449 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On June 3, 2022, the Board authorized the execution of a reverse split of the issued and outstanding shares of the Corporation’s common stock at a ratio of up to one post-split share per two thousand pre-split shares (1:2,000) at a time and exact ratio amount the Board of Directors deems appropriate. On September 2, 2022, FINRA approved a 1-for-2,000 reverse stock split of the Company’s common stock that was approved by the Company’s Board of Directors
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
108564879 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
108564879 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
107582614 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107582614 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001

Files In Submission

Name View Source Status
0001663577-23-000441-index-headers.html Edgar Link pending
0001663577-23-000441-index.html Edgar Link pending
0001663577-23-000441.txt Edgar Link pending
0001663577-23-000441-xbrl.zip Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
trfe-20230630.xsd Edgar Link pending
trfe10q2_063023.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
trfe-20230630_cal.xml Edgar Link unprocessable
trfe-20230630_lab.xml Edgar Link unprocessable
trfe-20230630_def.xml Edgar Link unprocessable
trfe-20230630_pre.xml Edgar Link unprocessable
trfe10q2_063023_htm.xml Edgar Link completed